Liquidia to Report Second Quarter 2022 Financial Results on August 11, 2022
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Liquidia Corporation (NASDAQ: LQDA) will announce its second quarter 2022 financial results on August 11, 2022, with a conference call scheduled for 8:30 a.m. ET. The call will cover financial results and a corporate update. Interested parties can join by phone or access a webcast, which will be archived for 30 days. Liquidia focuses on developing treatments for pulmonary hypertension, including its inhalation powder YUTREPIA™. For more information, visit Liquidia's website.
Positive
- Upcoming earnings announcement may provide insights into financial health.
- Focus on pulmonary hypertension treatment could signal growth potential.
Negative
- None.
Details
News Market Reaction – LQDA
The recorded move for LQDA in the trading session of this news was +0.38%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MORRISVILLE, N.C., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its second quarter 2022 financial results on Thursday, August 11, 2022. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update.
The live call may be accessed by dialing 1-800-715-9871 (domestic) or 1-646-307-1963 (international) and entering the conference code: 8369322. A webcast of the call will be available and archived for 30 days on Liquidia’s website at https://liquidia.com/index.php/investors/events-and-presentations.
About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its PRINT® Technology. The company operates through its two wholly owned subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia Technologies has developed YUTREPIA™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH). Liquidia PAH provides the commercialization for rare disease pharmaceutical products, such as generic Treprostinil Injection. For more information, please visit www.liquidia.com.
Contact Information for Media & Investors
Jason Adair
Senior Vice President, Corporate Development and Strategy
919.328.4400
jason.adair@liquidia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.